Side-by-side comparison
Amgen vs Johnson & Johnson
As of Sep 25, 2026, P/E is 25.8x for Amgen vs 31.5x for Johnson & Johnson; P/S is 5.9x for Amgen vs 6.7x for Johnson & Johnson; revenue growth is 9.1% for Amgen vs 8.1% for Johnson & Johnson; operating margin is 30.0% for Amgen vs 22.2% for Johnson & Johnson.
Key metrics
| Metric | AMGN | JNJ |
|---|---|---|
| Price | $414.61 | $271.22 |
| Market cap | $224.15B | $653.61B |
| P/E | 25.8x (#1) | 31.5x (#2) |
| P/S | 5.9x (#1) | 6.7x (#2) |
| Revenue growth | 9.1% (#1) | 8.1% (#2) |
| Operating margin | 30.0% (#1) | 22.2% (#2) |
| Net margin | 23.0% (#1) | 21.5% (#2) |
| Debt / equity | 4.44 (#2) | 0.44 (#1) |
| 1-year return | +51.9% (#1) | +50.9% (#2) |
| Research score | 67/100 (#1) | 65/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Johnson & Johnson (JNJ) — Drug Manufacturers—General